Background

• The calcitonin gene-related peptide (CGRP) monoclonal antibodies used for migraine prevention and CGRP receptor antagonists for abortive migraine treatment are being more utilized for migraine management.
• Though they have a similar mechanism of action, slight differences in their target may make the dual therapy of these agents more effective in managing migraines with minimal concerns of increased safety risks.
• Dual CGRP therapy could be a beneficial option for patients with contraindications, history of intolerance, or lack of benefit to other migraine medications.

Objectives

The aim of the study is to assess the risk of adverse drug reactions resulting in therapy discontinuation when taking preventative and abortive dual CGRP agents compared to monotherapy.

Read the Outcomes Study by submitting the form below.

​